Form 4: BioAge Labs Director James Healy Receives Stock Options
Statement of Changes in Beneficial Ownership
Director James Healy was granted 22,000 stock options in BioAge Labs, Inc. as part of a standard equity compensation arrangement.
Summary
- Director James Healy acquired 22,000 stock options in BioAge Labs, Inc. (BIOA).
- The options have an exercise price of $15.48 per share.
- The grant date for these options is June 10, 2026.
- The options are set to expire on June 9, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- The value of the options is dependent on the future market performance of BioAge Labs common stock.
- Vesting is contingent upon the reporting person's continued service to the issuer.
Future Outlook
The options vest on the earlier of the next annual meeting of stockholders or the one-year anniversary of the grant date, provided the director remains in service.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.
Comparison to Industry Standards
- The grant of stock options to non-employee directors is consistent with standard compensation practices for publicly traded biotech companies.
- The vesting schedule tied to annual meetings is a common mechanism to ensure director retention and alignment with the annual governance cycle.
Stakeholder Impact
- Minor potential dilution for shareholders if options are exercised in the future.
Next Steps
- Vesting of the 22,000 options on the earlier of the next annual meeting or June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of the option grant transaction. |
| 06/12/2026 | Date the Form 4 was filed with the SEC. |
| 06/09/2036 | Expiration date of the granted stock options. |
Keywords
BioAge Labs, BIOA, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.